Orlando, FL-A study from the University of Toronto has created a credo for urology patients who purchase products from the $27 billion nutritional supplement industry: "Caveat emptor"-let the buyer beware.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.